Danese, S, Vermeire, S, D'Haens, G, Panés, J, Dignass, A, Magro, F, Nazar, M, Le Bars, M, Lahaye, M, Ni, L, Bravata, I, Lavie, F, Daperno, M, Lukáš, M, Armuzzi, A, Löwenberg, M, Gaya, D R, Peyrin-Biroulet, L & STARDUST study group 2022, ' Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST) : an open-label, multicentre, randomised phase 3b trial ', The Lancet Gastroenterology and Hepatology, vol. 7, no. 4, pp. 294-306 . https://doi.org/10.1016/S2468-1253(21)00474-X lancet. Gastroenterology & hepatology, 7(4), 294-306. Elsevier Limited The Lancet Gastroenterology and Hepatology, 7(4), 294-306. Elsevier Ltd
Gossec, L, Siebert, S, Bergmans, P, de Vlam, K, Gremese, E, Joven-Ibáñez, B, Korotaeva, T V, Lavie, F, Noël, W, Nurmohamed, M T, Sfikakis, P P, Theander, E & Smolen, J S 2022, ' Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis : 1-year results from the real-world PsABio Study ', Annals of the Rheumatic Diseases, vol. 81, no. 6, 221640, pp. 823-830 . https://doi.org/10.1136/annrheumdis-2021-221640 Annals of the Rheumatic Diseases, 81(6):221640, 823-830. BMJ Publishing Group